Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.

Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, Xu Z, Chen Y.

J Exp Clin Cancer Res. 2019 Apr 8;38(1):149. doi: 10.1186/s13046-019-1161-8.

2.

A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.

Yang L, Zhang F, Wang X, Tsai Y, Chuang KH, Keng PC, Lee SO, Chen Y.

Oncotarget. 2016 Aug 23;7(34):55543-55554. doi: 10.18632/oncotarget.10837.

3.

Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.

Zhang F, Shen M, Yang L, Yang X, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y.

Cancer Biol Ther. 2017 Aug 3;18(8):606-615. doi: 10.1080/15384047.2017.1345391. Epub 2017 Jul 7.

4.

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

Yang L, Shen M, Xu LJ, Yang X, Tsai Y, Keng PC, Chen Y, Lee SO.

Sci Rep. 2017 Aug 11;7(1):7958. doi: 10.1038/s41598-017-08483-z.

5.

JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells.

Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT.

Int J Oncol. 2014 May;44(5):1643-51. doi: 10.3892/ijo.2014.2310. Epub 2014 Feb 21.

PMID:
24573038
6.

WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.

Meng J, Zhang XT, Liu XL, Fan L, Li C, Sun Y, Liang XH, Wang JB, Mei QB, Zhang F, Zhang T.

Cell Signal. 2016 Nov;28(11):1673-82. doi: 10.1016/j.cellsig.2016.07.008. Epub 2016 Jul 21.

PMID:
27449264
7.

FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.

Shen M, Tsai Y, Zhu R, Keng PC, Chen Y, Chen Y, Lee SO.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Mar;1863(3):313-322. doi: 10.1016/j.bbalip.2017.12.012. Epub 2018 Jan 3.

PMID:
29306075
8.

Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.

Wu YS, Chung I, Wong WF, Masamune A, Sim MS, Looi CY.

Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):296-306. doi: 10.1016/j.bbagen.2016.10.006. Epub 2016 Oct 14.

PMID:
27750041
9.

miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.

Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W.

Oncotarget. 2016 Apr 26;7(17):24510-26. doi: 10.18632/oncotarget.8229.

10.

PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/β-catenin signaling pathway.

Gao S, Hu J, Wu X, Liang Z.

Biomed Pharmacother. 2018 Dec;108:618-624. doi: 10.1016/j.biopha.2018.09.067. Epub 2018 Sep 20.

11.

Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.

Zheng B, Ren T, Huang Y, Guo W.

Biochem Biophys Res Commun. 2018 Jan 8;495(2):1695-1701. doi: 10.1016/j.bbrc.2017.12.032. Epub 2017 Dec 7.

PMID:
29225166
12.

NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.

Liu S, Sun J, Cai B, Xi X, Yang L, Zhang Z, Feng Y, Sun Y.

Tumour Biol. 2016 Jul;37(7):9671-80. doi: 10.1007/s13277-016-4848-x. Epub 2016 Jan 22.

PMID:
26801672
13.

Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.

Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L, Jiang H, Ren J, Cai J, Li Q.

BMC Cancer. 2015 Mar 5;15:97. doi: 10.1186/s12885-015-1119-y.

14.

Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.

Zhao Z, Cheng X, Wang Y, Han R, Li L, Xiang T, He L, Long H, Zhu B, He Y.

PLoS One. 2014 Apr 30;9(4):e95884. doi: 10.1371/journal.pone.0095884. eCollection 2014.

15.

ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.

Zhang L, Xu LJ, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX.

Mol Med Rep. 2018 May;17(5):7045-7054. doi: 10.3892/mmr.2018.8781. Epub 2018 Mar 20.

16.

IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway.

Yadav A, Kumar B, Datta J, Teknos TN, Kumar P.

Mol Cancer Res. 2011 Dec;9(12):1658-67. doi: 10.1158/1541-7786.MCR-11-0271. Epub 2011 Oct 5.

17.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.

18.

Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Epithelial-Mesenchymal Transition via STAT3 Signaling Pathway in Non-Small Cell Lung Cancer Cells.

Zhang W, Wu X, Hu L, Ma Y, Xiu Z, Huang B, Feng Y, Tang X.

Oncol Res. 2017 May 24;25(5):843-852. doi: 10.3727/096504016X14813880882288. Epub 2016 Dec 15.

PMID:
28508744
19.

CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.

Zhang R, Sun S, Ji F, Liu C, Lin H, Xie L, Yang H, Tang W, Zhou Y, Xu J, Li P.

Cell Physiol Biochem. 2017;43(2):465-480. doi: 10.1159/000480473. Epub 2017 Sep 1.

20.

Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.

Zhang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y.

Cancer Sci. 2016 Jun;107(6):746-54. doi: 10.1111/cas.12937. Epub 2016 May 3.

Supplemental Content

Support Center